Liposomal Curcumin is Better than Curcumin to Alleviate Complications in Experimental Diabetic Mellitus

Abstract

Curcumin (CC) is known to have anti-inflammatory and anti-oxidative properties and has already been tested for its efficiency in different diseases including diabetes mellitus (DM). New formulations and route administration were designed to obtain products with higher bioavailability. Our study aimed to test the effect of intraperitoneal (i.p.) administration of liposomal curcumin (lCC) as pre-treatment in streptozotocin(STZ)-induced DM in rats on oxidative stress, liver, and pancreatic functional parameters. Forty-two Wistar-Bratislava rats were randomly divided into six groups (seven animals/group): control (no diabetes), control-STZ (STZ-induced DM —60 mg/100g body weight a single dose intraperitoneal administration, and no CC pre-treatment), two groups with DM and CC pre-treatment (1mg/100g bw—STZ + CC1, 2 mg/100g bw—STZ + CC2), and two groups with DM and lCC pre-treatment (1 mg/100g bw—STZ + lCC1, 2 mg/100g bw—STZ + lCC1). Intraperitoneal administration of Curcumin in diabetic rats showed a significant reduction of nitric oxide, malondialdehyde, total oxidative stress, and catalase for both evaluated formulations (CC and lCC) compared to control group (p < 0.005), with higher efficacy of lCC formulation compared to CC solution (p < 0.002, excepting catalase for STZ + CC2vs. STZ + lCC1when p = 0.0845). The CC and lCC showed hepatoprotective and hypoglycemic effects, a decrease in oxidative stress and improvement in anti-oxidative capacity status against STZ-induced DM in rats (p < 0.002). The lCC also proved better efficacy on MMP-2, and -9 plasma levels as compared to CC (p < 0.003, excepting STZ + CC2 vs. STZ + lCC1 comparison with p = 0.0553). The lCC demonstrated significantly better efficacy as compared to curcumin solution on all serum levels of the investigated markers, sustaining its possible use as adjuvant therapy in DM.

Experimental model of acute myocardial infarction for evaluation of prevention and rehabilitation strategies in cardiovascular diseases – a pilot study

“…This will cause increased release of cardiac marker enzymes into the bloodstream, alternated ischemic electrocardiograph changes, accumulated lipid peroxides, and damaged cardiac function (6,7). Apart from oxidative stress, inflammation also plays an important role in the pathophysiology of AMI (8,9,10). The pathophysiological and morphologic alterations in the heart tissues of this drug-induced AMI experimental model are comparable with those taking place in human myocardial infarction (11,12).…”

Ramipril and resveratrol co‐treatment attenuates RhoA/ROCK pathway‐regulated early‐stage diabetic nephropathy‐associated glomerulosclerosis in streptozotocin‐induced diabetic rats

“…During the induction of diabetes, rats in the control group (n = 8) were intraperitoneally injected with a single dose of citric buffer solution (pH = 3.5), and rats in the STZ‐induced DM group (n = 32) were intraperitoneally injected with a single dose of STZ (15 mg/kg) freshly prepared in citric buffer solution (pH = 3.5). After 2 days of STZ injection, the serum glucose level of DM rats was monitored until the fasting serum glucose level was more than 20 mg/dL, and this was considered an STZ‐induced diabetic model . On the 36th day, control rats were treated with 1 mL phosphate‐buffered saline (PBS) per day for 10 days, and STZ‐induced DM rats were divided into 4 groups (n = 8 in each group).…”

“…After 2 days of STZ injection, the serum glucose level of DM rats was monitored until the fasting serum glucose level was more than 20 mg/dL, and this was considered an STZ-induced diabetic model. 22 On the 36th day, control rats were treated with 1 mL phosphate-buffered saline (PBS) per day for 10 days, and STZ-induced DM rats were divided into 4 groups (n = 8 in each group). The STZ-induced DM group rats were treated with 1 mL PBS per day for 10 days.…”

The Effect of Nano-Epigallocatechin-Gallate on Oxidative Stress and Matrix Metalloproteinases in Experimental Diabetes Mellitus

“…The following doses were used: STZ-60 mg/100 g body weight (b.w.) [40]; EGCG in saline solution or in liposomal form were freshly prepared and were administrated i.p. in a dose of 2.5 mg/100 g b.w./day as pretreatment, two consecutive days before STZ administration [41].…”